{
    "id": 2555,
    "fullName": "FGFR4 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FGFR4 over exp indicates an over expression of the Fgfr4 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2264,
        "geneSymbol": "FGFR4",
        "terms": [
            "FGFR4",
            "CD334",
            "JTK2",
            "TKF"
        ]
    },
    "variant": "over exp",
    "createDate": "11/11/2014",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13799,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Derazantinib (ARQ 087) inhibited growth of ovarian cancer cell lines harboring Fgfr4 overexpression in culture (PMID: 27627808).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 2900,
                "therapyName": "Derazantinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11276,
                    "pubMedId": 27627808,
                    "title": "Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27627808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1348,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited phosphorylation of FGFR4 and increased sensitivity of colon cancer cell lines to Adrucil (fluorouracil), resulting in increased apoptosis in culture (PMID: 24503538).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 5255,
                "therapyName": "BGJ398 + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1057,
                    "pubMedId": 24503538,
                    "title": "Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24503538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited phosphorylation of FGFR4 and increased sensitivity of colon cancer cell lines to Eloxatin (oxaliplatin), resulting in increased apoptosis in culture (PMID: 24503538).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 5256,
                "therapyName": "BGJ398 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1057,
                    "pubMedId": 24503538,
                    "title": "Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24503538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7150,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines demonstrated sensitivity to treatment with BGJ398 in culture, resulting in inhibition of FGFR4 phosphorylation and decreased cell growth (PMID: 24503538).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1057,
                    "pubMedId": 24503538,
                    "title": "Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24503538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rhabdomyosarcoma cells over expressing FGFR4 had increased sensitivity to Iclusig (ponatinib), resulting in decreased cell growth in culture (PMID: 24124571).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 88,
                    "pubMedId": 24124571,
                    "title": "Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24124571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12823,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1371 inhibited proliferation in transformed cells overexpressing wild-type FGFR4 in culture (PMID: 28978721).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 3583,
                "therapyName": "PRN1371",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10753,
                    "pubMedId": 28978721,
                    "title": "The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13092,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rhabdomyosarcoma cell lines with high FGFR4 expression due to a PAX3-FOXO1 fusion demonstrated sensitivity to growth inhibition by H3B-6527 in culture (PMID: 29247039).",
            "molecularProfile": {
                "id": 28909,
                "profileName": "PAX3 - FOXO1 FGFR4 over exp"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13802,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Derazantinib (ARQ 087) inhibited growth of leukemia cells harboring both Fgfr3 and Fgfr4 overexpression in culture (PMID: 27627808).",
            "molecularProfile": {
                "id": 29429,
                "profileName": "FGFR3 over exp FGFR4 over exp"
            },
            "therapy": {
                "id": 2900,
                "therapyName": "Derazantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11276,
                    "pubMedId": 27627808,
                    "title": "Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27627808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19459,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 inhibited proliferation of a breast cancer cell line with expression of FGF19 and KLB and overexpression of FGFR4 in culture (PMID: 31409633).",
            "molecularProfile": {
                "id": 34159,
                "profileName": "FGF19 pos FGFR4 over exp KLB pos"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2409,
            "profileName": "FGFR4 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 7572,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR4 over exp"
                },
                {
                    "id": 7573,
                    "name": "FGFR4 Inhibitor",
                    "profileName": "FGFR4 over exp"
                }
            ]
        },
        {
            "id": 28909,
            "profileName": "PAX3 - FOXO1 FGFR4 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29429,
            "profileName": "FGFR3 over exp FGFR4 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34159,
            "profileName": "FGF19 pos FGFR4 over exp KLB pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}